Ultima-Caber 0.25 - Ultima Pharmaceuticals

Cabergoline’s pharmacological profile is marked by its selective binding to dopamine D2 receptors, with minimal affinity for serotonin and adrenergic receptors. This specificity allows for targeted prolactin inhibition while reducing the likelihood of broader systemic side effects, such as those affecting mood or cardiovascular function. This makes Cabergoline particularly valuable in medical settings where focused prolactin control is essential. Its profile as an ergot derivative further ensures effective hormone modulation with fewer unwanted reactions, establishing it as a preferred treatment option for hyperprolactinemia​​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Ultima-Caber 0.25 by Ultima Pharmaceuticals, consult with your doctor or healthcare professional.